An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes
January 2006
Article
volume 253, issue 1 pp 16-20.
| Related Files |
|---|
|
Redirect to Publisher's version
(Publisher's version.url.txt, 43 bytes) |
Repository contains one additional file which is not publicly available
Abstract Anti-CD20 monoclonal antibody (rituximab) is effectively used in the treatment of B-cell lymphomas. Recent reports in the literature suggest that antibody associated autoimmune disorders may respond to rituximab. We therefore treated nine patients with anti-Hu or anti-Yo associated paraneoplastic neurological syndromes (PNS) with a maximum of four monthly IV infusions of rituximab (375mg/m(2)). In this uncontrolled, unblinded trial of rituximab, three patients improved > or =1 point on the Rankin Scale (RS). One patient with limbic encephalitis improved dramatically (RS from 5 to 1). Further studies of rituximab in autoantibody associated PNS are warranted.
Keywords
- Male
- Aged
- Aged, 80 and over
- Female
- Humans
- Middle Aged
- Treatment Outcome
- Antibodies, Monoclonal/ therapeutic use
- Antibodies/ metabolism
- Antineoplastic Agents/ therapeutic use
- Hu Paraneoplastic Encephalomyelitis Antigens/immunology
- Nerve Tissue Proteins/immunology
- Paraneoplastic Syndromes, Nervous System/ drug therapy/ immunology
